134 related articles for article (PubMed ID: 38348768)
1. Decoding the synergistic potential of MAZ-51 and zingerone as therapy for melanoma treatment in alignment with sustainable development goals.
Letsoalo K; Nortje E; Patrick S; Nyakudya T; Hlophe Y
Cell Biochem Funct; 2024 Mar; 42(2):e3950. PubMed ID: 38348768
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion.
Hlophe YN; Joubert AM
J Cell Mol Med; 2022 Dec; 26(23):5743-5754. PubMed ID: 36398426
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with zingerone and its novel derivative synergistically inhibits TGF-β1 induced epithelial-mesenchymal transition, migration and invasion of human hepatocellular carcinoma cells.
Kim YJ; Jeon Y; Kim T; Lim WC; Ham J; Park YN; Kim TJ; Ko H
Bioorg Med Chem Lett; 2017 Feb; 27(4):1081-1088. PubMed ID: 28110870
[TBL] [Abstract][Full Text] [Related]
4. Clinical markers and driving mechanisms in melanoma progression: VEGF-C, RhoC, c-Ski/SnoN and EGFR.
Boone B; Brochez L
Verh K Acad Geneeskd Belg; 2009; 71(5):251-94. PubMed ID: 20232784
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.
Spinella F; Caprara V; Di Castro V; Rosanò L; Cianfrocca R; Natali PG; Bagnato A
J Mol Med (Berl); 2013 Mar; 91(3):395-405. PubMed ID: 22965194
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
7. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
8. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
10. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study.
Massi D; Puig S; Franchi A; Malvehy J; Vidal-Sicart S; González-Cao M; Baroni G; Ketabchi S; Palou J; Santucci M
J Clin Pathol; 2006 Feb; 59(2):166-73. PubMed ID: 16443733
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
13. Zingerone suppresses cell proliferation via inducing cellular apoptosis and inhibition of the PI3K/AKT/mTOR signaling pathway in human prostate cancer PC-3 cells.
Qian S; Fang H; Zheng L; Liu M
J Biochem Mol Toxicol; 2021 Jan; 35(1):e22611. PubMed ID: 32905641
[TBL] [Abstract][Full Text] [Related]
14. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
15. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
[TBL] [Abstract][Full Text] [Related]
16. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
Špirić Z; Eri Ž; Erić M
Int J Surg Pathol; 2015 Dec; 23(8):629-37. PubMed ID: 25911567
[TBL] [Abstract][Full Text] [Related]
17. Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor.
Pocza P; Süli-Vargha H; Darvas Z; Falus A
Int J Cancer; 2008 May; 122(9):1972-80. PubMed ID: 18076073
[TBL] [Abstract][Full Text] [Related]
18. SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model.
Ackerman R; Backer JM; Backer M; Skariah S; Hamby CV
Toxins (Basel); 2010 Sep; 2(9):2242-57. PubMed ID: 22069683
[TBL] [Abstract][Full Text] [Related]
19. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
20. The role of the VEGF-C/VEGFR-3 axis in cancer progression.
Su JL; Yen CJ; Chen PS; Chuang SE; Hong CC; Kuo IH; Chen HY; Hung MC; Kuo ML
Br J Cancer; 2007 Feb; 96(4):541-5. PubMed ID: 17164762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
